Trial Profile
Pilot open label study of MD1003 (biotin) in the treatment of Progressive Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2015
Price :
$35
*
At a glance
- Drugs Biotin (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 22 Apr 2015 New trial record
- 17 Apr 2015 According to MedDay Pharmaceuticals media release, the results were published in the Journal of Multiple Sclerosis and Related Disorders.